Embodiments provide methods and apparatus for fabricating blood products, such as platelet-rich plasma, containing elevated concentrations of growth factors such as platelet derived growth factor. The platelet-rich plasma can be autologous, and the concentration of growth factors (e.g., platelet derived growth factor) is elevated relative to other samples isolated from the same subject. The platelet-rich plasma can be used to promote tissue regeneration, including wound healing, joint repair, hair growth, and the like. The compositions can be combined with stem cells and used to treat disorders otherwise treated with stem cells. The growth factors present in the samples can direct the differentiation of the stem cells.

A blood filtration system may to couple to an infusion pump that is external to the blood filtration system. The blood filtration system may include a blood circuit, for instance a variable-volume blood circuit. An infusion port may be in communication with the blood circuit and may receive an infusion fluid pumped by the infusion pump. A filtration pump may extract a filtrate fluid from a filter. The filtrate fluid may include filtered plasma constituents. A fluid characteristic sensor may measure one or more of pressure or flow rate of the infusion fluid pumped by the infusion pump. A controller may monitor the fluid characteristic sensor to determine a change in the pressure or flow rate of the infusion fluid. The controller may modulate a speed of the variable-speed filtration pump based on the change in the pressure or flow rate of the infusion fluid.

A tray for processing platelet rich fibrin includes a base having at least one alignment structure, a screen attachment having at least one alignment structure for engagement with the base, and a lid having at least one alignment structure for engagement with the base and the screen attachment. The screen attachment includes a screen offset between the top and bottom surface of the screen. When the screen attachment is placed on the base with the top surface facing upward, the lid is configured to compress a fibrin clot placed on the screen to a first thickness, and when the screen attachment is placed on the base with the bottom surface facing upward the lid is configured to compress a fibrin clot placed on the screen to a second thickness different from the first thickness.

System and method for pathogen inactivation with UV-C light (employed by itself or in addition to filtering out particulates rom the flow of air reaching the user) by delivering, into a lightguide portion of the air inactivation chamber of the system, a dose of ultraviolet radiation sufficient for at least one log reduction level of the pathogen while, at the same time, multiply reflecting the light inside the chamber to increase the irradiance of inactivating light several fold (up to 5×, or even up to 8.6×) as compared to that delivered to the chamber.

The present invention relates to various methods of treatment using a novel blood perfusion device. The blood perfusion device comprises a perfusion chamber comprising at least one compartment A and at least one compartment B, compartment A comprising a first opening which is in direct fluid communication to a second opening, wherein the first opening of compartment A is in direct fluid communication to a first port of the perfusion chamber and the second opening of compartment A is in direct fluid communication to a second port of the perfusion chamber; and compartment B comprising a first opening which is in direct fluid communication to a second opening, wherein the first opening of compartment B is in direct fluid communication to a third port of the perfusion chamber and the second opening of compartment B is in direct fluid communication to a fourth port of the perfusion chamber, wherein compartment A is separated from compartment B by at least one membrane, said membrane being configured to prevent cells from crossing the membrane.

Platelet rich plasma containing human very small embryonic-like stem cells (hVSEL) is treated with amplitude-modulated pulses of laser light having a predefined wavelength for a predefined time period, where the predefined wavelength ranges from 300 nm to 1000 nm. Treatment of the platelet rich plasma using this method results in an unexpectedly high degree of proliferation of the hVSEL in the platelet rich plasma, resulting in reduction of biological age, when administered to a patient.

Fluid processing assemblies and methods are provided for mononuclear cell collection. Mononuclear cells are separated from red blood cells in a blood separation chamber, with the mononuclear cells and then the red blood cells exiting the chamber via an outlet port. The mononuclear cells and then the red blood cells enter an outlet flow path that is in fluid communication with a mononuclear cell collection container. The outlet flow path includes a visual indicium, which an operator may use to determine the position of the red blood cells within the outlet flow path and when to end mononuclear cell collection by preventing fluid communication between the outlet flow path and the mononuclear cell collection container.

A system for collecting plasma comprises a separator to separate whole blood from a donor into a plasma product and a second blood component, an anticoagulant line to combine anticoagulant with the whole blood, a touchscreen, and a controller. The controller is configured to receive donor parameters electronically from a donor management system. The controller is configured to use a target volume for raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for raw plasma based on the total donor blood volume. The controller is configured to control the system to operate draw and return phases to withdraw whole blood from a donor and return the second blood component to the donor until a volume of raw plasma in the collection container equals the target volume of raw plasma.

A filtration cell (10) for a biological sample including an upper chamber for receiving the biological sample to be filtered, a lower chamber in fluid communication with the upper chamber, and a filtration membrane (14) positioned between the upper chamber and the lower chamber is disclosed. A surface of the filtration membrane has a contact angle >90°. The flow of the biological sample through the upper chamber may be tangential to the filtration membrane and a filtrate passing through the filtration membrane may be collected in the lower chamber. Also, a method of filtering a biological sample including passing the biological sample through an upper chamber of a filtration cell as described above and collecting a filtrate in the lower chamber is disclosed.

The present invention relates to a device for the treatment of blood comprising a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids. Suitable polypeptides are, for example, deoxyribonucleases, ribonucleases, DNA methyltransferases or cytosine deaminases. The invention further comprises the use of such devices for the treatment of patients suffering from chronic kidney failure, cancer or lupus erythematosus, as well as methods and systems for the treatment of blood, wherein free nucleic acids are inactivated outside the body.